Last Updated

10 Mar 2020

MVVC 2 - Field trials of a new combination malaria vaccine in West African Adults and Children

Objectives

The Malaria Vectored Vaccine Consortium (MVVC) 2 builds on the established network of MVVC 1, which aims to develop a malaria vaccine candidate, while building capacity at the African clinical trial sites and driving the development of a strong network of its partners.

This project will aim to determine whether addition of a circumsporozoite protein (CSP) particle in adjuvant will enhance the efficacy of vectored prime-boost vaccines for P. falciparum.

Principal Institution(s)

Principal Investigator
Thematic Categories

Date

2012 Dec - 2014 Nov

Total Project Funding

$1,431,430